Abstract. Epithelial ovarian cancer is a major cause of mortality among women with gynecological malignancies. Paclitaxel is commonly used for chemotherapy of ovarian cancer, yet its efficacy is limited by chemoresistance. Generally, drug resistance is associated with acquisition of the epithelial-mesenchymal transition (EMT) in cancer. The aim of the present study was to determine whether the EMT is involved in acquired resistance to paclitaxel in A2780 human ovarian cancer cells. Using the paclitaxel-resistant A2780/PTX cell line, we examined the cellular morphology, molecular changes, migration and proliferation consistent with the EMT. Furthermore, we found that inhibition of phosphatidylinositol 3-kinase (PI3K) activity reduced the proliferation and migration and restored their sensitivity to paclitaxel. Our study provides new insights into EMT-like phenotypic changes that are linked to paclitaxel resistance in A2780 cells. We believe that inhibition of the PI3K signaling pathway could provide a novel therapeutic approach to overcome chemoresistance and prevent metastasis during paclitaxel chemotherapy.

Introduction

Epithelial ovarian cancer is a major cause of mortality among women with gynecological malignancies due to its late symptomatology (1); it is often associated with distant metastases and has a poor prognosis (2). Chemotherapy is essential for the management of ovarian cancer, but the efficacy of this treatment is limited by chemoresistance. Paclitaxel is a first-line chemotherapeutic agent that is effective in epithelial ovarian cancer by stabilizing microtubules, inducing cell cycle arrest in the G2-M phase, and activating pro-apoptotic signaling (2,3). In spite of the comparatively high sensitivity of epithelial ovarian cancer to paclitaxel, the prognosis of advanced or recurrent cases remains poor since mortality is mostly the result of metastasis that is refractory to conventional chemotherapy (2).

The epithelial-mesenchymal transition (EMT) in cancer cells has been shown to promote metastasis and chemoresistance (4). During the acquisition of EMT characteristics, the hallmark of EMT is loss of the epithelial molecule E-cadherin and gain of mesenchymal markers including N-cadherin and vimentin, leading to remodeling of the cytoskeleton and enhancement of cancer cell migration and invasion (5). An EMT phenotype has been reported in gemcitabine-resistant pancreatic cancer cells (6), gefitinib-resistant non-small cell lung cancer and oxaliplatin-resistant colorectal cancer cells (7), paclitaxel-resistant ovarian cancer cells (2) and tamoxifen-resistant breast cancer cells (8). Blockade of the EMT pathways is critical for preventing cancer cell migration and invasion as well as for restoring drug sensitivity (4). Although the EMT in cancer cells integrates multiple signaling pathways, such as TGFβ, NF-κB, Wnt and Hedgehog (9-12), the details in A2780 human ovarian cancer cells remain to be identified.

We are the first to report that phosphatidylinositol 3-kinase (PI3K) inhibition reverses paclitaxel resistance-induced EMT in A2780 human ovarian cancer cells, indicating that the PI3K pathway is a promising therapeutic target against ovarian cancer with paclitaxel chemotherapy.

Materials and methods

Cells and reagents. A2780/WT and A2780/PTX cell lines were obtained from KeyGen Biotech Co. Ltd. (Nanjing, China) and maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin.
(100 U/ml penicillin and 100 µg/ml streptomycin) at 37°C in a humidified atmosphere of 5% CO₂. Paclitaxel was from Qilu Pharmaceutical Co., Ltd. (Jinan, China). LY294002 was from Selleckchem (Burlington, NC, USA). The primers were synthesized by Sangon Biotechnology (Shanghai, China).

**Reverse transcription (RT)-PCR.** Total RNA was extracted using the TRIZol protocol and cDNA was synthesized from the mRNA using the SuperScript First-Strand Synthesis System (Invitrogen Life Technologies, Carlsbad, CA, USA) for RT-PCR. PCR was performed for 35 cycles of 95°C for 30 sec, 58°C for 30 sec and 72°C for 45 sec. The values from triplicate readings were averaged.

**Paclitaxel chemosensitivity assay.** The cells were seeded at 8,000 cells/well (triplicates) in 96-well plates. After 24 h, they were treated with paclitaxel (1.5-1,500 µg/ml in 2-fold serial dilutions) for 48 h. After the treatment, MTS (20 µl; Promega Corporation, Madison, WI, USA) was added to each well and the cells were incubated at 37°C with 5% CO₂ for 4 h. Absorbance at 590 nm was then measured with a microplate reader (Thermo Synergy HT, USA).

**Immunofluorescence staining.** The cells were fixed for 30 min in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 10 min at room temperature, respectively. Cells were washed 3 times in PBS after each treatment. They were then blocked with 2% BSA in PBS for 30 min at room temperature, incubated with primary antibody for β-tubulin (20 µg/ml) diluted in 2% BSA/PBS overnight at 4°C, and then incubated with fluorescent secondary antibody for 1 h at room temperature. Images were acquired with a confocal laser scanning microscope (LSM 710; Carl Zeiss, Jena, Germany). If required, cells were pretreated with LY294002 (10 µM, 24 h).

**Results**

**Acquisition of paclitaxel resistance in A2780/PTX cells induces morphological and molecular changes consistent with EMT signaling.** We first examined the morphological characteristics of the cell lines during exponential growth. A2780/WT cells formed cohesive clusters with round cellular morphology in vitro (Fig. 1A), consistent with an epithelial phenotype. By contrast, A2780/PTX cells, grown in the presence of 100 nM PTX, displayed a spindle-like morphology and formed dyscohesive sheets (Fig. 1A).

To determine whether the acquisition of paclitaxel resistance induced specific molecular changes consistent with EMT, we investigated EMT-related biomarkers. Compared with the wild-type cells, the A2780/PTX cells showed significant reduction in E-cadherin and laminin-5 expression and upregulation of N-cadherin, vimentin and Twist (Fig. 1B).

**A2780/PTX cells display increased potential for proliferation and migration.** We performed wound healing and Transwell migration assays to compare the migratory potential between the 2 cell lines. The capacity for wound healing in A2780/PTX cells was significantly enhanced (Fig. 2A), and the relative numbers of migrating and invasive A2780/PTX cells were significantly superior to wild-type cells (Fig. 2B).

We further investigated the proliferative potential of A2780/WT and A2780/PTX cells at various times after plating and with various cell numbers at 48 h by assessing cell viability using a modified MTT assay. The MTT assay with various numbers showed a decrease in the growth of A2780/WT cells compared with A2780/PTX cells. In addition, similar results were found in the proliferative potential at various times (Fig. 2C).
PI3K signaling pathway is important for the induction of cell migration and proliferation. Recently, activation of the PI3K/AKT axis has been shown to be a central feature of EMT (13-16). To assess the involvement of PI3K signaling, the PI3K inhibitor LY294002 (10 µM) was applied to A2780/PTX cells, and they exhibited well-organized cell-
cell association, appeared cohesive, and exhibited classical epithelial morphology (Fig. 3A). The expression of epithelial marker laminin 5 was significantly enhanced, while the levels of mesenchymal marker N-cadherin decreased (Fig. 3E). Inhibition of PI3K significantly decreased migration and proliferation in A2780/PTX cells (Fig. 3B-D). These results...
showed that inhibition of PI3K signaling in A2780/PTX cells led to reversal of the EMT, indicating the involvement of the PI3K signaling pathway in the chemoresistance process.

**Inhibition of the PI3K activity increases sensitivity of A2780/PTX cells to paclitaxel.** We next explored whether inhibiting PI3K reverses the resistance to paclitaxel in A2780/PTX cells. MTT assays showed that A2780/PTX cells treated with LY294002 restored the sensitivity to paclitaxel-induced cell death (Fig. 3A). The IC₅₀ was reduced to half of that in untreated A2780/PTX cells.

**Inhibition of the PI3K activity alters the cytoskeleton of A2780/PTX cells.** The anticancer drug paclitaxel binds to β-tubulin in assembled microtubules and causes cytoskeleton changes in cells (17,18). We further investigated organization of the cytoskeleton in A2780/PTX cells. A2780/PTX cells had spindle-like morphology or filopodia formation, in which brightly stained longitudinal β-tubulin bundles were detected, whereas cells in the wild-type and LY294002-treated groups displayed polygonal cell shapes (Fig. 4).

**Discussion**

Chemoresistance remains the major therapeutic barrier in epithelial ovarian cancer (4,19). A thorough understanding of the mechanisms is essential for improving therapeutic agents. Our study used wild-type (A2780/WT) and paclitaxel-resistant human epithelial ovarian cancer cells (A2780/PTX) to investigate the molecular mechanism of paclitaxel resistance and associated cellular behaviors.

In the present study, we demonstrated that A2780/PTX cells underwent EMT processes. This was confirmed as follows: (i) morphological change from cobblestone-like to spindle-shaped cells; (ii) increased potential for proliferation and migration; and (iii) changes in molecular markers (significant reduction in E-cadherin and laminin-5 expression and upregulation of N-cadherin and vimentin). In agreement with our results, some reports have shown that the EMT is induced by other chemotherapeutic agents in different cancer cell lines (20-22). Moreover, several studies have demonstrated that the EMT plays an important role in functional malignancy behaviors including facilitating the transformation, initiation, progression and metastasis of human cancer (23,24). We further examined the proliferation in these 2 cell types. As expected, our findings showed that A2780/PTX cells displayed enhanced multiplication in the MTT assay. Overall, we obtained evidence that paclitaxel resistance and facilitated malignant potential are linked with the EMT.

Since the PI3K/AKT axis is frequently activated in human cancer (15), we focused on the EMT with particular emphasis on the PI3K/AKT pathways involved in the regulation of malignancy. To determine whether the PI3K pathway was involved in the process, the PI3K inhibitor LY294002 was applied to A2780/PTX cells, resulting in inhibition of fibroblastic morphology, proliferation and motility. Our evidence seems to be associated with other research in gefitinib-resistant cells from a head and neck squamous cell carcinoma cell line (22). Furthermore, we found that the inhibition of PI3K activity attenuated the paclitaxel resistance and led to loss of cell polarity in terms of β-tubulin distribution suggesting that there should also be defects in cell migration and invasion. Although further studies are required to elucidate the chemoresistance mechanisms in PI3K-mediated EMT, the use of PI3K inhibitors during chemotherapy could be a useful approach to improve its efficacy.

In conclusion, we have shown that the development of paclitaxel resistance in epithelial ovarian cancer cells is accompanied by inducible EMT-like changes with increased potential to metastasize. Targeting with the PI3K inhibitor LY294002 may sensitize cancer cells to chemotherapeutics and reduce motility. The clinical significance of the PI3K signal in acquired resistance to paclitaxel merits further investigation.

**Acknowledgements**

This study was supported by the Program for New Century Excellent Talents in University of The Ministry of Education of China (to X.M.); Fundamental Research Funds for the Central Universities JUSRP51111A (to X.M.); China National Natural Science Foundation grants 81100185 (to X.M.), 81130057 (to J.J.), 81201600 (to D.H.) and 81101667 (to R.Z.); Jiangsu Province National Natural Science Foundation grant BK2010161 (to D.H.); and a ’Strategic Priority Research Program’ grant from the Chinese Academy of Sciences XDA01040000 (to J.J.).

**References**


